Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,191,642
  • Shares Outstanding, K 607,111
  • Annual Sales, $ 2,122 M
  • Annual Income, $ 975,040 K
  • 60-Month Beta N/A
  • Price/Sales 10.94
  • Price/Cash Flow 23.00
  • Price/Book 2.36
Trade RPRX with:

Options Overview

Details
  • Implied Volatility 47.83%
  • Historical Volatility 21.78%
  • IV Percentile 56%
  • IV Rank 48.48%
  • IV High 67.54% on 08/07/20
  • IV Low 29.29% on 06/03/21
  • Put/Call Vol Ratio 5.50
  • Today's Volume 13
  • Volume Avg (30-Day) 292
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 9,584
  • Open Int (30-Day) 14,403

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.70
  • Number of Estimates 4
  • High Estimate 0.72
  • Low Estimate 0.68
  • Prior Year 0.73
  • Growth Rate Est. (year over year) -4.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.68 +0.62%
on 08/02/21
42.89 -11.60%
on 07/06/21
-4.33 (-10.24%)
since 07/02/21
3-Month
37.68 +0.62%
on 08/02/21
47.10 -19.50%
on 06/07/21
-6.08 (-13.83%)
since 04/30/21
52-Week
34.80 +8.95%
on 10/29/20
53.23 -28.77%
on 01/19/21
-5.13 (-11.93%)
since 07/31/20

Most Recent Stories

More News
Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U.S. financial markets open. The company will...

RPRX : 37.85 (-0.92%)
MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma

PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution...

MOR : 14.03 (+0.86%)
RPRX : 37.85 (-0.92%)
Royalty Pharma Declares Third-Quarter 2021 Dividend

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share.

RPRX : 37.85 (-0.92%)
Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"):

RPRX : 37.85 (-0.92%)
Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of June:

RPRX : 37.85 (-0.92%)
Constellation (CNST) Surges on Takeover Deal With MorphoSys

Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.

INCY : 77.89 (+0.70%)
RPRX : 37.85 (-0.92%)
MOR : 14.03 (+0.86%)
CNST : 33.99 (+0.06%)
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys' $1.7 billion acquisition of Constellation...

RPRX : 37.85 (-0.92%)
CNST : 33.99 (+0.06%)
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma

MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals,...

MOR : 14.03 (+0.86%)
CNST : 33.99 (+0.06%)
RPRX : 37.85 (-0.92%)
MorphoSys to Acquire Constellation Pharmaceuticals

--Bolsters Position in Hematology-Oncology and Expands into Solid Tumors

MOR : 14.03 (+0.86%)
CNST : 33.99 (+0.06%)
RPRX : 37.85 (-0.92%)
Royalty Pharma Reports First Quarter 2021 Results

-- Increased Adjusted Cash Receipts guidance for 2021

RPRX : 37.85 (-0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 39.47
2nd Resistance Point 39.11
1st Resistance Point 38.65
Last Price 37.85
1st Support Level 37.84
2nd Support Level 37.48
3rd Support Level 37.03

See More

52-Week High 53.23
Fibonacci 61.8% 46.19
Fibonacci 50% 44.01
Fibonacci 38.2% 41.84
Last Price 37.85
52-Week Low 34.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar